We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Johnson & Johnson subsidiary Janssen has launched a human clinical trial of its experimental Ebola vaccine in the UK, with much larger clinical trials expected to start this spring in the U.S. and Africa. Read More
Gilead Sciences has signed an exclusive deal with CVS Health Corp. to cover its hepatitis C drugs Sovaldi and Harvoni, a move that follows rival AbbVie’s exclusive deal late last month with pharmacy benefit giant Express Scripts to cover its combination therapy. Read More
Ranbaxy’s 180-day marketing exclusivity period for its version of Novartis’ blockbuster hypertension drug Diovan ended yesterday, prompting a flood of generic competition. Read More
The FDA this year aims to answer key questions on which quality metrics it will collect from drugmakers, how to develop biosimilars and how to use social media to promote products. Read More
Washington state oncology drug developer OncoGenex is taking back rights to the experimental cancer therapy custirsen, ending a five-year collaboration with Israeli manufacturer Teva Pharmaceuticals. Read More
In a closely watched case, a federal judge has denied Celgene’s motion to dismiss a lawsuit alleging the brandmaker engaged in anticompetitive conduct by refusing to turn over product samples for ANDA bioequivalence testing. Read More
With the FDA stepping up scrutiny of data integrity during facility inspections, drugmakers must be ready to answer tough questions about their electronic record system, an inspections expert said. Read More